Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen

Ilkka J Helenius, Heikki O Tikkanen, Tari Haahtela

Abstract

Objectives—To study factors affecting the occurrence of exercise induced bronchospasm (EIB) in elite runners.

Methods—Fifty eight elite runners, 79% of them belonging to Finnish national teams, volunteered. The athletes answered a questionnaire on respiratory symptoms. Skin prick tests were used to investigate atopy, and spirometry to examine lung function at rest and after an exercise challenge test (ECT) at subzero temperature in the winter and after a similar ECT in the summer at the end of the birch pollen season.

Results—Definitive EIB (a post-exercise reduction of 10% or more in forced expiratory volume in one second (FEV1)) was observed in five (9%) of the 58 runners. A subgroup consisting of 19 non-atopic symptom-free runners with no family history of asthma was used to establish a normal range for post-exercise reduction in FEV1. When this group's mean exercise induced change in FEV1, minus 2 SDs (a reduction of 6.5% or more in FEV1) was taken as the lower limit of the reference range, 15 (26%) of the runners had probable EIB in either the winter or the pollen season. The occurrence of probable EIB depended on atopy (odds ratio increased with number of positive skin prick test reactions, p<0.05). Nine (22%) of the 41 runners, challenged in both the winter and the pollen season, had probable EIB only in the winter, and three (7%) had it only in the pollen season. Only one runner (2%) had EIB in both tests.

Conclusions—Mild EIB is common in Finnish elite runners and is strongly associated with atopy. Seasonal variability affects the occurrence of EIB, and thus exercise testing should be performed in both cold winter air and the pollen season to detect EIB in elite runners.


Keywords: exercise induced bronchospasm; atopy; seasonal variability; athletes

Exercise induced bronchospasm (EIB) in athletes has been observed by several investigators, who have reported widely different prevalences. In the 1984 United States Olympic team, 11% of the athletes had EIB. Of 983 new intercollegiate athletes, 2.8% had EIB on treadmill exercise challenge tests (ECTs). Of 1530 Swiss athletes, 1.4% had a decrease of 10% or more in their forced expiratory volume in one second (FEV1) after an ECT indoors. Rupp et al10 studied 166 college athletes, and observed that a combination of symptom history and spirometry was not sufficient for the adequate detection of EIB in high school athletes. However, most studies on the occurrence of EIB in athletes have been carried out only in athletes complaining of exercise induced respiratory symptoms, and do not reflect the true occurrence of EIB in elite athletes.

EIB can be modified using different air temperature and humidity conditions during the ECT.11 Bronchospasm in connection with exercise is enhanced by cold dry air12 and in pollen allergic asthmatics by pollen.7 8 In Finland, athletes train under varying climatic conditions. Inhalation of cold dry air in winter during exercise has been shown to provoke bronchospasm in susceptible runners.7 In the spring and summer, athletes are exposed to pollen.10 To clarify the effects of such seasonal factors on EIB in elite athletes, we subjected an unselected population of elite runners to ECTs in the winter at subzero temperature and in the pollen season.

Methods

SUBJECTS

Fifty eight unselected runners volunteered for the study, 46 of whom belonged to Finnish national teams. In eight (14%) asthma had been diagnosed, in all cases the diagnosis having been made during the runner's active sports career. Four of these asthmatics inhaled steroid regularly; one inhaled sodium cromoglycate, one inhaled nedocromil sodium, and all inhaled ß2 agonists as needed. The runners had competed for a mean of 9.8 (range 2-20) years. Their main events ranged from 400 m to the marathon. They had run a mean distance of 4170 (range 2000–8500) km in the previous year. Table 1 characterises the study group further. All subjects gave their informed written consent. The protocol was approved by the local ethics committee.

STUDY DESIGN

The first part of the study was carried out in February-March 1994. It included a winter ECT at the Finnish Sports Institute (Vierumäki, Finland) (table 2) and further studies at the Helsinki University Central Hospital, where the runners answered a questionnaire, were interviewed by one of the authors (I H), and were subjected to skin prick tests (SPTs)
and a resting spirometric examination. The second part of the study, in May-June 1994, at the Finnish Sports Institute, included a pollen season ECT. Of the 58 runners studied, 54 performed the ECT in the winter, 46 in the pollen season, and 41 performed both tests.

The birch pollen counts used to identify the birch pollen season were from Kangasala, 100 km west of Vierumäki, indicating roughly the pollen situation in Southern Finland, where all the runners were living. The pollen season ECTs were performed soon after the highest pollen counts (fig 1); pretest exposure is an even better predictor of risk of EIB than the actual exposure during the ECT. A volumetric seven day Burkard sampler (Burkard Manufacturing Co.) was used to trap pollen. Samples were analysed at the Aerobiology Unit, University of Turku. Figure 1 shows weekly pollen counts and timing of the ECTs.

**EXERCISE CHALLENGE TESTS**

The ECT consisted of running 2000 m outdoors on the cross country track of the Finnish Sports Institute. To achieve uniform exercise and ventilatory responses, runners were instructed to raise their heart rates in a controlled manner. They carried on the wrist a heart rate meter and recorder (Sport Tester TM PE 3000, Polar Electro Ky, Kempele, Finland), from which they could see their heart rate.

The athletes did no warm up exercises or training before the ECT on the test day. Inhaled β2 agonists and cromones were withheld for 12 hours before the ECT, but inhaled steroids were used unrestricted. During the first 500 m of the ECT, the athletes accelerated, raising their heart rates to 85% of their personal maximum, which was calculated from the formula 205 – 0.5 × age. The runners ran the remaining 1500 m without changing the running velocity reached.

FEV1 was measured using a pocket sized spirometer (Vitalograph Escort, Vitalograph Ltd, Buckingham, UK), which was calibrated daily. Measurements were made indoors at a temperature of 20–22°C and a relative humidity of 50–65%. Subjects wore nose clips. Measurements were made immediately before and at 4, 10 and 20 minutes after exercise. Each time, in a standing position, the runners made three spirometry efforts, and the best result of the three was used. To measure EIB, the maximal change in FEV1 was calculated as 100% × ([post-exercise FEV1 − pre-exercise FEV1]/pre-exercise FEV1). As a measure of bronchospasm we used the maximal value of the percentage change in FEV1 (positive or negative).

All runners had FEV1 values within the reference (normal) range before the ECT (table 2). The mean outdoor temperature during the ECT was −6.6°C in the winter and +8.3°C in the pollen season. The mean running time was 37 seconds longer (p<0.01) in the winter than in the pollen season; this was due to the slippery conditions encountered in the winter. Mean maximal heart rates were similar on both occasions.

**Table 1** Characteristics of the study population of 58 elite runners

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women/men</td>
<td>15/43</td>
</tr>
<tr>
<td>Mean (SD) age (years)</td>
<td>24.0 (5.6)</td>
</tr>
<tr>
<td>Members of national teams, No (%)</td>
<td>46 (79)</td>
</tr>
<tr>
<td>History of exercise induced bronchial symptoms, No (%)</td>
<td>18 (31)</td>
</tr>
<tr>
<td>Mean (SD) FVC</td>
<td></td>
</tr>
<tr>
<td>In litres</td>
<td>5.28 (0.98)</td>
</tr>
<tr>
<td>As % of predicted*</td>
<td>101.4 (10.4)</td>
</tr>
<tr>
<td>Mean (SD) FEV1</td>
<td></td>
</tr>
<tr>
<td>In litres</td>
<td>4.59 (0.86)</td>
</tr>
<tr>
<td>As % of predicted*</td>
<td>100.7 (10.6)</td>
</tr>
<tr>
<td>Mean (SD) PEF</td>
<td></td>
</tr>
<tr>
<td>In litres/second</td>
<td>11.11 (2.00)</td>
</tr>
<tr>
<td>As % of predicted*</td>
<td>109.6 (13.2)</td>
</tr>
</tbody>
</table>

*Reference values were those of Viljanen. FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PEF, peak expiratory flow.

**Table 2** Climatic conditions, pre-exercise forced expiratory volume in one second (FEV1) and performance of the runners in the winter and pollen season exercise challenge test. Values are means (SD)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Winter</th>
<th>Pollen season</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air temperature (°C)</td>
<td>−6.6 (4.9)</td>
<td>8.3 (4.0)</td>
</tr>
<tr>
<td>Water content (g/m3)</td>
<td>2.8 (1.2)</td>
<td>5.9 (1.6)</td>
</tr>
<tr>
<td>Pre-exercise FEV1</td>
<td>4.81 (0.83)</td>
<td>4.78 (0.76)</td>
</tr>
<tr>
<td>% of predicted*</td>
<td>104.2 (12.1)</td>
<td>102.4 (10.6)</td>
</tr>
<tr>
<td>Maximal heart rate (beats/min)</td>
<td>176 (10)</td>
<td>174 (8)</td>
</tr>
<tr>
<td>Running time</td>
<td>7 min 16 s (50 s)</td>
<td>6 min 49 s (47 s)</td>
</tr>
</tbody>
</table>

*Reference values were those of Viljanen.
Exercise induced bronchospasm in elite runners

**SPTs AND ATOPY**

SPTs were carried out with ten common airborne allergens and positive (histamine dihydrochloride, 10 mg/ml) and negative (solvent) control solutions from ALK (Soluprick SQ, 10 histamine equivalent pricks (HEP); Allergologisk Laboratorium, Horsholm, Denmark). The allergens were as follows: birch, Cladosporium herbarum; cat, Der p mite (Dermatophagoides pteronyssinus); and mould spores of Cladosporium herbarum. A subject was classified as atopic if any allergen caused a weal of 3 mm or larger in diameter than negative controls. Runners who had positive skin tests to birch pollen and symptoms of rhinoconjunctivitis in the birch pollen season were considered allergic to birch pollen.

**SPIROMETRY AT REST**

Resting flow volume spirometry was carried out with a Medikro 909 spirometer (Medikro OY, Kuopio, Finland). Subjects wore nose clips. Three reasonably reproducible efforts, with less than 5% difference between the two best ones, were required. FEV₁, forced vital capacity, and peak expiratory flow were measured, and values for the best effort were used in each case. Values were expressed as percentages of reference (predicted) values for adult Finns.

**RESULTS**

Means (SD) are given. To examine differences between groups, we used the Mann-Whitney U test, the Wilcoxon signed rank sum test, the McNemar test, and the χ² test for trend. For correlations, Spearman's rank correlation test was used. Two-tailed p values below 0.05 were considered significant.

**STATISTICAL ANALYSIS**

Means (SD) are given. To examine differences between groups, we used the Mann-Whitney U test, the Wilcoxon signed rank sum test, the McNemar test, and the χ² test for trend. For correlations, Spearman's rank correlation test was used. Two-tailed p values below 0.05 were considered significant.

**TABLE 3**

<table>
<thead>
<tr>
<th>Number of positive SPT reactions</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1–2</td>
<td>3.13</td>
<td>0.63 to 15.45</td>
</tr>
<tr>
<td>3–4</td>
<td>4.17</td>
<td>0.80 to 21.64</td>
</tr>
<tr>
<td>≥5</td>
<td>4.69</td>
<td>0.75 to 29.27*</td>
</tr>
</tbody>
</table>

*χ² test for trend, p<0.05.

**RESPIRATORY SYMPTOM QUESTIONNAIRE**

The questionnaire was based on the recommendations of Ferris and was used in our previous study. Questions concerned the occurrence of asthma, allergy, asthma medication, family history of asthma, symptoms of hay fever, and exercise induced bronchial symptoms. The latter were considered to occur if symptoms (shortness of breath, wheeze, cough) had been observed repeatedly during the last year. Answers to the self-administered questionnaire were confirmed in interviews.

**Figure 2**

Maximal post-exercise changes in forced expiratory volume in one second (FEV₁) in either the winter or pollen season exercise challenge test in the control runners and in runners with any risk factor (exercise induced bronchial symptoms, family history of asthma, atopy).
pollen season. Of the ten runners with birch pollen allergy, two had probable EIB in the winter, two in the pollen season, and six had no bronchospasm. Of the 31 non-birch pollen allergic runners, seven had probable EIB only in the winter, one only in the pollen season, and one had EIB on both occasions.

**Discussion**

We found definitive EIB in 9% of unselected Finnish elite runners. However, a much larger proportion of the runners (26%) have EIB, if a more sensitive approach is used. A large proportion of the runners with EIB were unaware of the condition. ECTs were carried out in both the winter and the pollen season; in most cases EIB occurred only in one season. Atopy was strongly associated with EIB, and the risk of EIB also increased with the number of positive SPT reactions.

**VALIDITY OF THE DATA**

The elite runners participated in carefully controlled outdoor ECTs, consisting of a 2000 m run on the cross country track of the Finnish Sports Institute. Our study may underestimate the magnitude of EIB, because four of the runners studied used regularly inhaled steroids, which have been shown to decrease exercise induced pulmonary changes.\(^{14}\)\(^{19}\)

No generally accepted reference (normal) range for exercise induced pulmonary changes in athletes exists. EIB was defined in two ways. Firstly, a cut off point of reduction of 10% or more in FEV\(_1\) was used according to the European Respiratory Society’s recommendations.\(^{13}\)

Secondly, we used the mean maximal post-exercise change in FEV\(_1\) minus 2 SDs obtained for the 19 runners with the lowest risk of bronchoconstriction (non-atopic, symptom-free, no family history of asthma). A maximal reduction of 6.5% or more in FEV\(_1\) was out of range and considered probable EIB. We have used this approach before\(^{13,14}\) and it also has been found useful in studies on children with atopy or chronic lung disease.\(^{20-22}\)

**COMPARISON WITH PREVIOUS FINDINGS**

Exercise testing for bronchospasm has been rarely performed in normal training conditions in elite athletes. Previously, Mannix et al\(^b\) performed lung function measurements in figure skaters after four or five minutes of strenuous skating routines. They observed EIB in 35% of the 124 skaters studied when using a cut off point of 10% for maximal post-exercise fall in FEV\(_1\). This is comparable with the 19% prevalence that we observed in runners in cold winter air.

Like Karjalainen et al\(^a\) we found that the exercise response of the runners who were not allergic to birch pollen attenuated in the warmer and more humid pollen season compared with the cold dry winter weather. Of the runners who were allergic to birch pollen, two, who showed a normal response in the winter, exhibited an abnormal response in the pollen season. This indicates seasonal variability of EIB, but the athlete population studied was too small to draw any definite conclusions. Karjalainen et al\(^a\) observed a non-significant increase in EIB during the pollen season compared with winter weather in asthmatics allergic to birch pollen. However, variation in EIB cannot be totally explained by environmental conditions such as air temperature, humidity, and allergen exposure.\(^{24}\)

We have previously reported that 17% of long distance runners and 8% of speed and power athletes have been diagnosed as having asthma.\(^{15}\) A much larger proportion of the athletes reported symptoms compatible with EIB. However, as shown now by us, 60% of the athletes with probable EIB had no previous indications of asthma. These findings as well as those of Mannix et al\(^b\) suggest that all competitive athletes should be tested for the possibility of EIB under conditions similar to those encountered during training and competition. Owing to the marked variability of EIB, exercise testing in cold winter weather and in the pollen season may be particularly relevant in pollen allergic athletes.

It would be interesting to know the prevalence with which EIB occurs in healthy non-athletes undertaking exercise under conditions resembling those studied here. We did not include a control group in the present study, because the tests performed on the athletes would be difficult to carry out on sedentary control subjects. Some conclusions can be drawn from studies on young adults in compulsory military service: a 6% prevalence rate of EIB has been found.\(^{20-26}\)

As shown also by Rupp et al\(^a\), athletes with EIB can by no means always be identified using history of symptoms and resting spirometry alone. In a clinical situation, evaluation of the risk for EIB in athletes is most important. Thus history of exercise induced bronchial symptoms gave 40% of runners with EIB in the present study, and asking for a family history of asthma gave 13% more. However, use of SPTs for atopy identified 47% more runners with EIB. Thus SPTs for atopy are obviously helpful when evaluating the risk.

**ATOPY AND SPORTS**

The present study confirms our previous findings that atopic allergy is a significant risk factor for EIB in elite athletes, even if they have no other indications of asthma.\(^{1}\) In a recent study, Brutsche et al\(^d\) found a significant relation between EIB and the presence of allergen specific IgE in healthy soldiers subjected to exercise tests after the main pollen season. Djukanovic et al\(^f\) have suggested that mild bronchial mucosal inflammation exists in atopic non-asthmatic patients, the condition being intermediate between that seen in asthmatics and healthy persons. Natural pollen exposure in pollen sensitive asthmatics affects T cell and mast cell function in the bronchial mucosa.\(^{20}\) Long exposure to pollen allergens during training and competition, especially in runners sensitised to pollen allergens, may be manifested as an abnormal response to exercise as found in this study.

We found that a relatively high proportion of the runners (50%) were atopic, and, in the
Exercise induced bronchospasm in elite runners

We thank Docent Fred Björksten (Helsinki, Finland) for his expert comments. Mrs Leena Petman, Mrs Alli Tallqvist, Mrs Anne Bruce, and Mr Timo Vuorimaa, M.Sc., are acknowledged for technical help. We thank also the athletes who participated in the study. This study was supported by the Finnish Allergy Research Foundation, the Finnish Sports Research Foundation, the Finnish Medical Foundation, the Ida Montin Foundation, and the Finnish Anti-Tuberculocous Association Foundation.

Commentary

This Finnish trial set out to study the factors that affect recurrence of exercise induced bronchospasm in their elite national teams and whether they include cold dry air in the winter and birch pollen in the summer. A group of elite runners volunteered and were studied with skin tests and exercise challenge tests at subzero temperatures and during the pollen season. The results were analysed to find out the incidence of exercise induced asthma. Exercise induced asthma was defined in this study in two ways, firstly as a reduction of 10% or more in FEV1 after exercise, and secondly using the mean maximal post-exercise change in FEV1 minus two standard deviations of an number of runners with lowest risk of bronchoconstriction.

The outcome was interesting in that the number of subjects who suffered from exercise induced bronchospasm within the group was much higher than has been reported in other trials, but, as the authors point out, many athletes are unaware that they suffer from bronchospasm, and it may be that these athletes think that their particular response to exercise is normal. It would be interesting to compare these 58 runners who volunteered with 58 controls, but, as the authors state, this is technically very difficult to do in view of the fact that controls are not able to run at the speeds that elite Finnish runners can maintain.

PETER THOMAS
Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen.
I J Helenius, H O Tikkanen and T Haahtela

doi: 10.1136/bjsm.32.2.125

Updated information and services can be found at:
http://bjsm.bmj.com/content/32/2/125

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/